Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech ...

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Delaware says COVID-19 vaccines are available at state clinics, regardless of insurance status. But only 2 clinics carried ...

Roivant Sciences Ltd (ROIV) showcases robust cash reserves and promising late-stage trials, while navigating competitive pressures and legal proceedings.

CereCura was co-founded by renowned scientist and UBC professor Pieter Cullis, who developed LNPs, the drug delivery system ...

In conclusion, Immunovant’s earnings call reflected a positive outlook with significant achievements in clinical trials and a strong financial position. Despite facing competitive pressures and data ...

CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Invest conference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR) is part of ...

Background Immunogenicity to SARS-CoV-2 vaccination in patients with SLE varies by vaccine type and immune-modulating therapy. However, data in Southeast Asian populations, especially among Thai ...

Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...